FEVIPIPRANT
Total Payments
$20.1M
Transactions
1,629
Doctors
249
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.2M | 226 | 1 |
| 2019 | $5.3M | 393 | 84 |
| 2018 | $10.3M | 431 | 93 |
| 2017 | $3.4M | 579 | 123 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $20.0M | 1,071 | 99.6% |
| Consulting Fee | $40,241 | 9 | 0.2% |
| Food and Beverage | $21,955 | 420 | 0.1% |
| Travel and Lodging | $18,462 | 127 | 0.1% |
| Education | $12.35 | 2 | 0.0% |
Payments by Type
Research
$20.0M
1,071 transactions
General
$80,670
558 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO STANDARD-OF-CARE ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED ASTHMA | Novartis Pharmaceuticals Corporation | $4.7M | 0 |
| A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO STANDARD OF CARE ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED ASTHMA | Novartis Pharmaceuticals Corporation | $4.3M | 0 |
| A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE EOSINOPHILIC ASTHMA | Novartis Pharmaceuticals Corporation | $3.6M | 0 |
| A TWO TREATMENT EPOCH RANDOMIZED PLACEBO CONTROLLED MULTI CENTERED PARALLEL GROUP STUDY TO ASSESS THE SAFETY OF QAW039 WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA | Novartis Pharmaceuticals Corporation | $2.7M | 0 |
| A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA | Novartis Pharmaceuticals Corporation | $2.6M | 0 |
| A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY PARALLEL GROUP PLACEBO CONTROLLED STUDY OF FEVIPIPRANT ONCE DAILY PLUS STANDARD OF CARE SOC FOR REDUCTION OF SYSTEMIC CORTICOSTEROIDS ORAL AND PARENTERAL USE IN PATIENTS WITH SEVERE ASTHMA | Novartis Pharmaceuticals Corporation | $505,544 | 1 |
| AN OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO ASSESS THE PHARMACOKINETICS OF FEVIPIPRANT (QAW039) IN PATIENTS WITH HEPATIC IMPAIRMENT COMPARED TO MATCHED HEALTHY SUBJECTS | Novartis Pharmaceuticals Corporation | $456,143 | 0 |
| AN OPEN LABEL SINGLE SEQUENCE CROSS OVER STUDY TO EVALUATE THE EFFECT OF CYCLOSPORINE ON THE PHARMACOKINETICS OF FEVIPIPRANT QAW039 IN HEALTHY VOLUNTEERS INCLUDING AN OPTIONAL RELATIVE BIOAVAILABILITY PART | Novartis Pharmaceuticals Corporation | $319,134 | 0 |
| AN OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO ASSESS\NTHE PHARMACOKINETICS OF FEVIPIPRANT (QAW039) IN PATIENTS\NWITH END-STAGE RENAL DISEASE ON HEMODIALYSIS AND\NOPTIONALLY IN PATIENTS WITH SEVERE TO MODERATE AND\NMILD RENAL IMPAIRMENT COMPARED TO MATCHED\NHEALTHY VOLUNTEERS INCLUDING A CROSS-OVER ASSESSMENT IN\NEND-STAGE RENAL DISEASE PATIENTS ON THE EFFECT OF DIALYSIS\NON FEVIPIPRANT PHARMACOKINETICS | Novartis Pharmaceuticals Corporation | $236,823 | 0 |
| PROSPECTIVE COMPARISON OF ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR ARNI VERSUS ACE INHIBITOR TRIAL TO DETERMINE IMPACT ON SERIOUS EVENTS AFTER MYOCARDIAL INFARCTION PARADISE MI | Novartis Pharmaceuticals Corporation | $166,972 | 0 |
| A MULTI-CENTER, PROOF-OF-MECHANISM STUDY OF MULTIPLE, ORAL DOSES OF FEVIPIPRANT (QAW039) IN COPD PATIENTS WITH SPUTUM EOSINOPHILIA | Novartis Pharmaceuticals Corporation | $116,654 | 0 |
| A MULTICENTER, OPEN-LABEL, 8 DAY TREATMENT STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF FEVIPIPRANT DELIVERED VIA ONCE DAILY CHEWABLE TABLET IN CHILDREN AGED 6 TO <12 YEARS WITH ASTHMA | Novartis Pharmaceuticals Corporation | $74,982 | 0 |
| A COMPARISON OF ENTRESTO VALSARTAN SACUBITRIL AND ANGIOTENSIN CONVERTING ENZYME INHIBITOR ACEI UTILIZATION AMONG VETERANS WITH HEART FAILURE AND REDUCED EJECTION FRACTION | Novartis Pharmaceuticals Corporation | $69,125 | 0 |
| A TWO TREATMENT EPOCH RANDOMIZED PLACEBO CONTROLLED MULTI CENTERED PARALLEL GROUP STUDY TO ASSESS THE SAFETY OF QAW039 WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA | NOVARTIS PHARMACEUTICALS CORPORATION | $66,959 | 0 |
| A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO STANDARD-OF-CARE ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED ASTHMA | NOVARTIS PHARMACEUTICALS CORPORATION | $48,462 | 0 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP PLACEBO CONTROLLED STUDY OF FEVIPIPRANT ONCE DAILY PLUS STANDARD OF CARE SOC FOR ASSESSMENT OF THE EFFICACY IN REDUCTION OF NASAL POLYPS SIZE IN PATIENTS WITH NASAL POLYPOSIS AND CONCOMITANT ASTHMA | Novartis Pharmaceuticals Corporation | $46,979 | 0 |
| A MULTICENTER, OPEN-LABEL, 8 DAY TREATMENT STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF FEVIPIPRANT DELIVERED VIA ONCE DAILY CHEWABLE TABLET IN CHILDREN AGED 6 TO <12 YEARS WITH ASTHMA | NOVARTIS PHARMACEUTICALS CORPORATION | $10,000 | 0 |
| A DOUBLE BLIND PLACEBO CONTROLLED STUDY EXAMINING THE EFFECT OF ORALLY ADMINISTERED QAW039 450 MG QD ON FEV1 AND ACQ IN NON ATOPIC ASTHMATIC PATIENTS WITH A BASELINE PRE BRONCHODILATOR FEV1 OF 40 TO 80 PERCENT PREDICTED INADEQUATELY CONTROLLED WITH LOW DOSE ICS THERAPY | Novartis Pharmaceuticals Corporation | $6,048 | 0 |
| A multicenter, open-label, 8 day treatment study to assess the pharmacokinetics, safety and tolerability of fevipiprant delivered via once daily chewable tablet in children aged 6 to <12 years with asthma | Novartis Pharmaceuticals Corporation | $5,000 | 0 |
| A multicenter, open-label, 8 day treatment study to assess the pharmacokinetics, safety and tolerability of fevipiprant delivered via once daily chewable tablet in children aged 6 to <12 years with asthma | NOVARTIS PHARMACEUTICALS CORPORATION | $3,500 | 0 |
Top Doctors Receiving Payments for FEVIPIPRANT
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cincinnati, OH | $20.0M | 1,071 |
| , M.D | Family Medicine | Carson City, NV | $6,829 | 5 |
| , D.O | Allergy | Pittsburgh, PA | $6,504 | 11 |
| , MD | Internal Medicine | Chelsea, MI | $6,220 | 7 |
| , M.D | Family Medicine | Lake View Terrace, CA | $6,121 | 5 |
| , M.D | Pediatrics | San Francisco, CA | $5,046 | 6 |
| , MD MS | Internal Medicine | Aurora, CO | $3,029 | 5 |
| Neil Minkoff | — | Wellesley, MA | $2,226 | 1 |
| , MD | Allergy & Immunology | Madison, WI | $1,308 | 1 |
| Mayank Shukla | Sleep Medicine | Brooklyn, NY | $1,250 | 1 |
| , MD | Specialist | Winter Park, FL | $1,164 | 10 |
| , M.D | Allergy & Immunology | San Antonio, TX | $1,153 | 1 |
| , MD | Allergy & Immunology | Huntington Beach, CA | $1,079 | 7 |
| , MD | Pulmonary Disease | Lihue, HI | $1,010 | 15 |
| , MD | Allergy & Immunology | Colorado Springs, CO | $898.50 | 7 |
| , M.D | Internal Medicine | San Diego, CA | $891.10 | 6 |
| , MD | Allergy & Immunology | Skillman, NJ | $699.32 | 4 |
| , D.O | Student in an Organized Health Care Education/Training Program | Cleveland, OH | $697.45 | 7 |
| , MD | Pediatrics | High Point, NC | $688.78 | 8 |
| , MD | Pulmonary Disease | Waterbury, CT | $683.00 | 1 |
| , MD | Sleep Medicine | Greenville, SC | $646.00 | 1 |
| , MD | Allergy & Immunology | Brooklyn, NY | $642.11 | 6 |
| , M.D | Family Medicine | Rock Hill, SC | $602.32 | 2 |
| Lyndon Mansfield | — | El Paso, TX | $592.23 | 7 |
| David Pearlman | — | Denver, CO | $579.86 | 6 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $20.1M
- Total Doctors 249
- Transactions 1,629
About FEVIPIPRANT
FEVIPIPRANT is a drug associated with $20.1M in payments to 249 healthcare providers, recorded across 1,629 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $1.2M was paid across 226 transactions to 1 doctors.
The most common payment nature for FEVIPIPRANT is "Unspecified" ($20.0M, 99.6% of total).
FEVIPIPRANT is associated with 20 research studies, including "A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO STANDARD-OF-CARE ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED ASTHMA" ($4.7M).